RxDoctor Payments DataLook up a doctor →

Edward McClay, MD

Medical Oncology · San Marcos, CANPI 1497727465

Payments from drug & device makers

$2,179,747in general payments, 2019–2025

Across 1,038 payments — averaging $2099.95 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Novartis$519K
  • Tesaro, Inc.$488K
  • Genentech, Inc.$259K
  • GSK$206K
  • E.r. Squibb & Sons, L.L.C.$160K
  • Seagen Inc.$139K
  • plus $408K from 54 others
$2,727in research payments, 2019–2025

Across 29 payments — averaging $94.05 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.

  • EMD Serono, Inc.$3K

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

CompanyPaymentsTotal
Novartis77$518,934
Tesaro, Inc.23$488,234
Genentech, Inc.41$258,890
GSK52$205,651
E.r. Squibb & Sons, L.L.C.164$160,030
Seagen Inc.61$139,441
EMD Serono, Inc.62$130,040
Array Biopharma Inc34$113,735
Beigene, Ltd.24$55,719
Incyte Corporation83$39,349
Eli Lilly5$35,571
Amgen26$8,520
Pfizer40$5,753
Mirati Therapeutics, Inc.7$5,311
Regeneron4$3,500
Sanofi11$3,087
Bristol Myers Squibb12$1,597
Merck44$875
Pharmacyclics LLC, An Abbvie Company29$656
Exelixis Inc.24$478
AstraZeneca(2 entities)22$477
Gilead20$382
Beigene USA, Inc.14$357
Takeda Pharmaceuticals U.S.A., Inc.12$251
Johnson & Johnson(2 entities)17$250
Regeneron Healthcare Solutions, Inc.8$235
AbbVie10$229
Coherus Oncology, Inc.12$218
Eisai Inc.10$216
Genentech USA, Inc.11$210
Astellas Pharma US Inc8$177
Bayer8$145
Puma Biotechnology, Inc.5$109
Tersera Therapeutics LLC4$74
Boehringer Ingelheim4$69
Daiichi Sankyo Inc.4$69
Karyopharm Therapeutics Inc.3$68
Accord Healthcare, Inc.2$45
EUSA Pharma (US) LLC2$44
Teva Pharmaceuticals USA, Inc.2$43
AVEO Pharmaceuticals, Inc.2$42
Pharmacosmos Therapeutics Inc.2$40
Blueprint Medicines Corporation2$40
Lilly USA, LLC2$38
Tolmar Pharmaceuticals, Inc.2$34
Tempus AI, Inc1$30
Cumberland Pharmaceuticals, Inc.2$29
Secura Bio, Inc.2$28
Sun Pharmaceutical Industries Inc.2$28
Taiho Oncology, Inc.1$26
Ipsen Biopharmaceuticals, Inc1$24
Morphosys, US Inc.1$24
GE HealthCare1$24
AMAG Pharmaceuticals, Inc.1$23
Myovant Sciences Inc.1$22
Sanofi-aventis U.S. LLC1$22
Acrotech Biopharma Inc.1$22
Stemline Therapeutics Inc.1$22
Agios Pharmaceuticals, Inc.1$22
Partner Therapeutics, Inc.1$20

How this compares

$2,179,747 in reported general payments places this provider in the 85th percentile of 379 medical oncology providers in California.

See all medical oncology providers in California →

Medicare billing

Part B allowed, 2024
$5,093,195
Medicare patients
567
Services billed
172,268

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Other medical oncology in San Marcos

See the full list for California →

Where these figures come from

Is this you, or does something look wrong? →